These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20052966)

  • 1. Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy.
    Yuan J; Page DB; Ku GY; Li Y; Mu Z; Ariyan C; Gallardo HF; Roman RA; Heine AI; Terzulli SL; Ritter E; Gnjatic S; Ritter G; Jungbluth AA; Allison JP; Old LJ; Wolchok JD
    Cancer Immun; 2010 Jan; 10():1. PubMed ID: 20052966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profile of ipilimumab and its role in the treatment of metastatic melanoma.
    Patel SP; Woodman SE
    Drug Des Devel Ther; 2011; 5():489-95. PubMed ID: 22267918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
    Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
    Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic basis for clinical response to CTLA-4 blockade in melanoma.
    Snyder A; Makarov V; Merghoub T; Yuan J; Zaretsky JM; Desrichard A; Walsh LA; Postow MA; Wong P; Ho TS; Hollmann TJ; Bruggeman C; Kannan K; Li Y; Elipenahli C; Liu C; Harbison CT; Wang L; Ribas A; Wolchok JD; Chan TA
    N Engl J Med; 2014 Dec; 371(23):2189-2199. PubMed ID: 25409260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.
    Lipson EJ; Drake CG
    Clin Cancer Res; 2011 Nov; 17(22):6958-62. PubMed ID: 21900389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
    Graziani G; Tentori L; Navarra P
    Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies.
    Ascierto PA
    Tumori; 2013; 99(6):302e-5e. PubMed ID: 24503809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint blockade in patients with melanoma metastatic to the brain.
    Di Giacomo AM; Margolin K
    Semin Oncol; 2015 Jun; 42(3):459-65. PubMed ID: 25965364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.
    Weber JS; Kudchadkar RR; Yu B; Gallenstein D; Horak CE; Inzunza HD; Zhao X; Martinez AJ; Wang W; Gibney G; Kroeger J; Eysmans C; Sarnaik AA; Chen YA
    J Clin Oncol; 2013 Dec; 31(34):4311-8. PubMed ID: 24145345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
    Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C
    Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients.
    Wistuba-Hamprecht K; Martens A; Heubach F; Romano E; Geukes Foppen M; Yuan J; Postow M; Wong P; Mallardo D; Schilling B; Di Giacomo AM; Khammari A; Dreno B; Maio M; Schadendorf D; Ascierto PA; Wolchok JD; Blank CU; Garbe C; Pawelec G; Weide B
    Eur J Cancer; 2017 Mar; 73():61-70. PubMed ID: 28167454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.
    Romano E; Kusio-Kobialka M; Foukas PG; Baumgaertner P; Meyer C; Ballabeni P; Michielin O; Weide B; Romero P; Speiser DE
    Proc Natl Acad Sci U S A; 2015 May; 112(19):6140-5. PubMed ID: 25918390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.
    Downey SG; Klapper JA; Smith FO; Yang JC; Sherry RM; Royal RE; Kammula US; Hughes MS; Allen TE; Levy CL; Yellin M; Nichol G; White DE; Steinberg SM; Rosenberg SA
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6681-8. PubMed ID: 17982122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An immune-active tumor microenvironment favors clinical response to ipilimumab.
    Ji RR; Chasalow SD; Wang L; Hamid O; Schmidt H; Cogswell J; Alaparthy S; Berman D; Jure-Kunkel M; Siemers NO; Jackson JR; Shahabi V
    Cancer Immunol Immunother; 2012 Jul; 61(7):1019-31. PubMed ID: 22146893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ipilimumab in the treatment of melanoma.
    Trinh VA; Hwu WJ
    Expert Opin Biol Ther; 2012 Jun; 12(6):773-82. PubMed ID: 22500861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-lasting responses under treatment with ipilimumab: an argument against maintenance therapy?
    Dick J; Enk A; Hassel JC
    Dermatology; 2015; 230(1):8-10. PubMed ID: 25531526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Metastatic malignant melanoma. Successfull treatment with ipilimumab].
    Jansen T; Bruch-Gerharz D; Reifenberger J; Schulte KW
    Hautarzt; 2013 Apr; 64(4):228, 230-1. PubMed ID: 23576166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma.
    Smyth MJ; Yagita H; McArthur GA
    J Clin Oncol; 2016 Apr; 34(12):e104-6. PubMed ID: 25311221
    [No Abstract]   [Full Text] [Related]  

  • 19. The proportion of circulating CD45RO
    Tietze JK; Angelova D; Heppt MV; Reinholz M; Murphy WJ; Spannagl M; Ruzicka T; Berking C
    Eur J Cancer; 2017 Apr; 75():268-279. PubMed ID: 28242504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Not Available].
    Mateus C; Libenciuc C; Robert C
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.